An FDA advisory panel has unanimously recommended that the multiple sclerosis drug Tysabri be returned to the market.
The drug was withdrawn about a year ago after it was found to cause a deadly brain ailment.
It is expected that the FDA will follow the recommendation, making Tysabri the second instance ever of a drug returning to the market after being withdrawn for safety reasons.
Shares in Elan and Biogen, the manufacturers of the drug, jumped upward in response to the news.
About one in 1,000 people who took Tysabri during clinical trials developed progressive multifocal leukoencephalopathy (PML), a rare brain disease that results in death or severe disablement. There is no treatment for PML.
Full Article
# posted by madthumbs @ 8:42 PM
